Subscribe
shutterstock_1334894144_igorgolovniov
IgorGolovniov / Shutterstock.com
6 June 2023Muireann Bolger

Indivior avoids multi-state antitrust trial with $100m payout

Case involved the alleged monopolisation of an opioid addiction treatment | More than 40 attorneys general had filed complaints against the pharma company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Indivior parts with $30m in Suboxone dispute
22 August 2023   The pharmaceutical company agreed to pay millions to resolve a multi-district antitrust suit brought by more than 40 US state attorneys | Company sued over alleged actions aimed at preserving the monopoly of anti-addiction drug.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
Indivior parts with $30m in Suboxone dispute
22 August 2023   The pharmaceutical company agreed to pay millions to resolve a multi-district antitrust suit brought by more than 40 US state attorneys | Company sued over alleged actions aimed at preserving the monopoly of anti-addiction drug.

More on this story

Big Pharma
Indivior parts with $30m in Suboxone dispute
22 August 2023   The pharmaceutical company agreed to pay millions to resolve a multi-district antitrust suit brought by more than 40 US state attorneys | Company sued over alleged actions aimed at preserving the monopoly of anti-addiction drug.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility